LOGIN  |  REGISTER
Amneal Pharmaceuticals
C4 Therapeutics

GE HealthCare Management to Present at Upcoming Investor Conferences

February 14, 2024 | Last Trade: US$81.76 1.16 -1.40

CHICAGO / Feb 14, 2024 / Business Wire / GE HealthCare (Nasdaq: GEHC), is announcing today that its Vice President and Chief Financial Officer, Jay Saccaro, will be presenting at the following upcoming investor conferences.

  • Citi Unplugged MedTech and Life Sciences Access Day – February 29, 2024 at 10:15 am ET in New York City
  • Oppenheimer Annual Healthcare MedTech and Services Conference (Virtual) – March 12, 2024 at 12:00 pm ET
  • Barclays Global Healthcare Conference – March 14, 2024 at 8:00 am ET in Miami

These events can be accessed by visiting GE HealthCare’s Investor Relations website: https://investor.gehealthcare.com/news-events/events on the dates and times listed above.

About GE HealthCare Technologies Inc.

GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 100 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient’s journey across the care pathway. Together our Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from diagnosis, to therapy, to monitoring. We are a $19.6 billion business with 51,000 employees working to create a world where healthcare has no limits.

Follow us on LinkedIn, X (formerly Twitter), and Insights for the latest news, or visit our website gehealthcare.com for more information.

Terns Pharmaceuticals

Stock Quote

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB